Oral @entity416 is a highly active, well-tolerated and convenient treatment for breast and @entity14 . This trial assessed the efficacy and safety of single-agent @entity416 in @entity1 with previously treated @entity43 . A total of 29 @entity1 with @entity902 -pretreated relapsed @entity43 were enrolled in this prospective, open-label, single-centre, phase II study. @entity1 received oral @entity416 1250 mg m(-2) twice daily on days 1-14 of a 21-day cycle. @entity5 response was evaluated using serum @entity10224 . Out of 29 enrolled @entity1 , 28 were evaluable, and a response was observed in eight @entity1 (29%, 95% confidence interval (CI), 13-49%). Median progression-free and overall survivals were 3.7 (95% CI, 2.8-4.6) and 8.0 (95% CI, 4.1-11.8) months, respectively. After 6 months of treatment, 28% (95% CI, 13-48%) of @entity1 remained progression-free and 62% (95% CI, 42-79%) were still alive. The most common clinical adverse events were @entity8566 ( @entity8566 ), @entity390 and @entity294 . Grade 3 @entity8566 occurred in 14% of @entity1 , grade 3 @entity391 in 10%. Efficacy and safety of @entity416 compare favourably with other monotherapies in @entity902 -refractory epithelial @entity43 . The convenience and improved safety profile of @entity416 compared with intravenous. regimens make it an ideal agent for administration in the outpatient setting.

A phase II trial of XXXX (Xeloda) in recurrent @entity43 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity5 :: ('MESH:D009369', 'Disease') :: ['Tumour'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhoea'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity8566 :: ('MESH:D060831', 'Disease') :: ['hand-foot syndrome', 'HFS'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity10224 :: ('94025', 'Gene') :: ['CA125'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum']
@entity416 :: (MESH:C110904,Chemical) :: ['capecitabine']
